Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 26 04:00PM ET
2.88
Dollar change
-0.27
Percentage change
-8.57
%
IndexRUT P/E- EPS (ttm)-2.30 Insider Own69.30% Shs Outstand60.34M Perf Week-6.80%
Market Cap186.97M Forward P/E- EPS next Y-1.88 Insider Trans-0.14% Shs Float19.93M Perf Month-32.55%
Income-136.67M PEG- EPS next Q-0.51 Inst Own30.29% Short Float8.69% Perf Quarter-31.75%
Sales2.23M P/S83.84 EPS this Y11.11% Inst Trans-1.52% Short Ratio8.07 Perf Half Y94.59%
Book/sh3.06 P/B0.94 EPS next Y8.02% ROA-32.26% Short Interest1.73M Perf Year-9.15%
Cash/sh2.66 P/C1.08 EPS next 5Y- ROE-56.07% 52W Range1.28 - 5.51 Perf YTD-13.25%
Dividend Est.- P/FCF- EPS past 5Y15.24% ROI-59.06% 52W High-47.73% Beta1.42
Dividend TTM- Quick Ratio9.92 Sales past 5Y-14.25% Gross Margin-343.76% 52W Low125.00% ATR (14)0.40
Dividend Ex-Date- Current Ratio9.92 EPS Y/Y TTM-1.45% Oper. Margin-5600.94% RSI (14)36.41 Volatility15.15% 11.51%
Employees165 Debt/Eq0.26 Sales Y/Y TTM-57.01% Profit Margin-6115.12% Recom1.33 Target Price14.40
Option/ShortYes / Yes LT Debt/Eq0.25 EPS Q/Q-21.14% Payout- Rel Volume0.75 Prev Close3.15
Sales Surprise-84.12% EPS Surprise-20.50% Sales Q/Q-48.56% EarningsMar 14 BMO Avg Volume214.51K Price2.88
SMA20-18.33% SMA50-29.34% SMA200-2.23% Trades Volume161,005 Change-8.57%
Date Action Analyst Rating Change Price Target Change
Aug-28-23Downgrade JP Morgan Overweight → Neutral $28 → $5
Dec-27-22Initiated Chardan Capital Markets Buy $19
Oct-31-22Initiated Guggenheim Buy $15
Oct-10-22Initiated Canaccord Genuity Buy $28
May-23-22Initiated H.C. Wainwright Buy $27
May-12-22Initiated William Blair Mkt Perform
Jul-13-21Initiated Piper Sandler Overweight $38
Jul-13-21Initiated JP Morgan Overweight $40
Jul-13-21Initiated BofA Securities Buy $34
Apr-23-24 07:00AM
Apr-11-24 08:25AM
07:00AM
Apr-08-24 04:05PM
Mar-25-24 07:00AM
07:00AM Loading…
Mar-19-24 07:00AM
Mar-14-24 01:52PM
07:30AM
Mar-08-24 11:55PM
Mar-07-24 09:55AM
Mar-05-24 06:03PM
Feb-01-24 07:00AM
Dec-09-23 12:00PM
Dec-07-23 11:01AM
Dec-06-23 07:30AM
07:30AM Loading…
07:30AM
Dec-05-23 08:55AM
Nov-21-23 07:00AM
Nov-14-23 03:58PM
Nov-09-23 08:29AM
07:01AM
07:00AM
07:00AM
Nov-02-23 09:00AM
Sep-26-23 07:00AM
Aug-09-23 08:50AM
07:30AM
Aug-01-23 06:48AM
May-12-23 06:11AM
May-11-23 08:55AM
07:30AM Loading…
07:30AM
Apr-17-23 07:00AM
Apr-12-23 08:30AM
Mar-16-23 08:55AM
07:30AM
Mar-15-23 04:01PM
Feb-21-23 07:00AM
Feb-08-23 07:30AM
Feb-01-23 07:00AM
Jan-17-23 09:35AM
Jan-09-23 10:46AM
Jan-06-23 08:23AM
Jan-05-23 04:01PM
Jan-04-23 07:00AM
Dec-08-22 10:02AM
Nov-22-22 07:00AM
Nov-11-22 07:00AM
Nov-10-22 08:45AM
07:30AM
Nov-02-22 07:05AM
Oct-05-22 04:05PM
Oct-03-22 07:00AM
Sep-26-22 07:00AM
Sep-06-22 07:00AM
Aug-25-22 07:30AM
Aug-11-22 08:45AM
07:30AM
Jul-07-22 01:43PM
Jul-01-22 09:18AM
Jun-24-22 04:30PM
Jun-21-22 04:30PM
Jun-06-22 07:30AM
May-20-22 03:04PM
May-16-22 07:30AM
May-03-22 04:30PM
May-02-22 04:30PM
Apr-18-22 04:30PM
Apr-06-22 04:30PM
Mar-23-22 04:30PM
Mar-17-22 07:30AM
Feb-09-22 04:05PM
Jan-22-22 11:29AM
Jan-14-22 06:50AM
Jan-10-22 12:27PM
11:12AM
08:08AM
06:59AM
Jan-04-22 04:30PM
Dec-17-21 07:00AM
Dec-16-21 06:30AM
Nov-22-21 08:00AM
Nov-10-21 07:30AM
Nov-04-21 09:00AM
Oct-07-21 07:30AM
Sep-17-21 04:01PM
Aug-12-21 08:00AM
Jun-22-21 04:01PM
Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. It focuses on harnessing the power of adult stem cells to develop curative allogeneic cell therapies for cancer. The company was founded by Marcela Maus and Hiromitsu Nakauchi in 2018 and is headquartered in Philadelphia, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Russotti GregorySee RemarksApr 22 '24Sale3.105,00015,490297,319Apr 24 04:17 PM
Farid AdrienneChief Operations OfficerMar 07 '24Option Exercise1.0322,83123,516136,980Mar 08 06:29 PM
Farid AdrienneChief Operations OfficerMar 07 '24Sale5.1422,831117,342114,149Mar 08 06:29 PM
Farid AdrienneChief Operations OfficerMar 06 '24Option Exercise1.0330,68431,605144,833Mar 08 06:29 PM
Farid AdrienneChief Operations OfficerMar 06 '24Sale4.9630,684152,340114,149Mar 08 06:29 PM
Farid AdrienneChief Operations OfficerFeb 16 '24Option Exercise1.03485500114,634Feb 21 04:10 PM
Farid AdrienneChief Operations OfficerFeb 16 '24Sale4.864852,358114,149Feb 21 04:10 PM
Farid AdrienneChief Operations OfficerFeb 06 '24Sale4.491,7848,005114,149Feb 07 05:21 PM
Carr DouglasSVP Finance & OperationsFeb 06 '24Sale4.495572,499303,580Feb 07 05:21 PM
Farid AdrienneChief Operations OfficerFeb 05 '24Sale3.842,0357,816115,933Feb 07 05:21 PM
Carr DouglasSVP Finance & OperationsFeb 05 '24Sale3.846432,470304,137Feb 07 05:21 PM